Effects of Aerobic Exercise Therapy through Nordic Walking Program in Lactate Concentrations, Fatigue and Quality-of-Life in Patients with Long-COVID Syndrome: A Non-Randomized Parallel Controlled Trial

dc.contributor.authorLaguarta-Val, Sofía
dc.contributor.authorVarillas-Delgado, David
dc.contributor.authorLizcano Álvarez, Ángel
dc.contributor.authorMolero-Sánchez, Alberto
dc.contributor.authorMelian-Ortiz, Alberto
dc.contributor.authorCano-de-la-Cuerda, Roberto
dc.contributor.authorJiménez-Antona, Carmen
dc.date.accessioned2025-01-07T08:24:29Z
dc.date.available2025-01-07T08:24:29Z
dc.date.issued2024-02-11
dc.description.abstractBackground: Long-COVID syndrome comprises a variety of signs and symptoms that develop during or after infection with COVID-19 which may affect the physical capabilities. However, there is a lack of studies investigating the effects of Long-COVID syndrome in sport capabilities after suffering from COVID-19 infection. The purpose of the study was to evaluate and compare lactate concentration and quality of life (QoL) in patients with Long-COVID with those who have not developed non-Long-COVID during Nordic walking exercise therapy. Methods: Twenty-nine patients (25.5 ± 7.1 years) took part in a non-randomized controlled trial, divided into two groups: a Long-COVID group (n = 16) and a non-Long-COVID control (n = 13). Patients were confirmed as having Long-COVID syndrome if they experienced fatigue or tiredness when performing daily activities and worsening of symptoms after vigorous physical or mental activity. All participants underwent a 12-week Nordic Walking program. Lactate concentration after exercise and distance covered during all sessions were measured. Pre- and Long-Nordic Walking program, the Modified Fatigue Impact Scale (MFIS), the Short Form 36 Health Survey (SF-36), and EURO QoL-5D (EQ-ED) were administered to assess fatigue and quality of life, respectively. Results: There was a lactate concentration effect between groups (F = 5.604; p = 0.024). However, there was no significant effect as a result of the session (F = 3.521; p = 0.121) with no interaction of group × session (F = 1.345; p = 0.414). The group main effect (F = 23.088; p < 0.001), time effect (F = 6.625; p = 0.026), and group × time (F = 4.632; p = 0.002) interaction on the SF-36 scale were noted. Also, there were a significant group main effect (F = 38.372; p < 0.001), time effect (F = 12.424; p = 0.005), and group × time interaction (F = 4.340; p = 0.014) on EQ-5D. However, there was only a significant group main effect (F = 26.235; p < 0.001) with no effect on time (F = 2.265; p = 0.160) and group × time (F = 1.584; p = 0.234) interaction on the MFIS scale. Conclusions: The Long-COVID group showed higher lactate concentration compared with the control group during the 12 weeks of the Nordic Walking program. The Long-COVID group presented a decrease in fatigue with respect to the control group according to the MFIS scale, as well as improvement in quality of life after aerobic exercise therapy.
dc.identifier.citationLaguarta-Val, S.; Varillas-Delgado, D.; Lizcano-Álvarez, Á.; Molero-Sánchez, A.; Melian-Ortiz, A.; Cano-de-la-Cuerda, R.; Jiménez-Antona, C. Effects of Aerobic Exercise Therapy through Nordic Walking Program in Lactate Concentrations, Fatigue and Quality-of-Life in Patients with Long-COVID Syndrome: A Non-Randomized Parallel Controlled Trial. J. Clin. Med. 2024, 13, 1035
dc.identifier.doihttps://doi.org/10.3390/jcm13041035
dc.identifier.issn2077-0383
dc.identifier.urihttps://hdl.handle.net/10115/50697
dc.language.isoen
dc.publisherMDPI
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectLong-COVID
dc.subjectCOVID-19
dc.subjectfatigue
dc.subjectquality of life
dc.subjectlactate concentration
dc.subjectaerobic exercise
dc.subjectNordic Walking program
dc.titleEffects of Aerobic Exercise Therapy through Nordic Walking Program in Lactate Concentrations, Fatigue and Quality-of-Life in Patients with Long-COVID Syndrome: A Non-Randomized Parallel Controlled Trial
dc.typeArticle

Archivos

Bloque original

Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Articulo_Definitivo_Revista.pdf
Tamaño:
753.25 KB
Formato:
Adobe Portable Document Format